ADVFN - Advanced Financial Network.
HOME» NYSE » C » CHK Stock Price » CHK Stock News

Chesapeake Share News

 Chesapeake Energy Corp. Stock Price
CHK Stock Price
 Chesapeake Energy Corp. Stock Chart
CHK Stock Chart
 Chesapeake Energy Corp. Stock News
CHK Stock News
 Chesapeake Energy Corp. Company Information
CHK Company Information
 Chesapeake Energy Corp. Stock Trades
CHK Stock Trades


Among the companies with shares expected to actively trade in Tuesday's session are Chesapeake Energy Corp. (CHK), LeCroy Corp. (LCRY) and Vertex Pharmaceutical Inc. (VRTX). Activist investor Carl Icahn reported a 7.6% stake in Chesapeake Energy on Friday and called for the replacement of at least four of the embattled natural gas company's current board members. The company said it would "carefully review" his request. Shares were up 2.8% premarket. Teledyne Technologies Inc. (TDY) has agreed to acquire LeCroy Corp. (LCRY) for roughly $240.6 million in cash, in a bid to extend offerings of test and measurement products. The deal values LeCroy at $14.30, a 56% premium to its most recent closing price. Shares climbed 55% to $14.16 premarket. Vertex Pharmaceutical Inc. (VRTX) revised the interim results of a recent clinical trial of cystic-fibrosis patients that had exceeded expectations and boosted hopes that the drug therapy tested could have blockbuster sales potential. Shares dropped 21% to $51.55 in premarket trade as the company said 35% of patients receiving the combination therapy experienced an improvement in lung function of at least 5 percentage points, down from the 46% first reported this month. The American depositary shares of Spanish banks tumbled premarket Tuesday as fresh worries about Spain's banking system arose following the government's announcement of a $24 billion bailout of Bankia, its third-largest lender by assets. The news sent Spanish borrowing costs up to 2012 highs. Banco Bilbao Vizcaya Argentaria SA (BBVA) fell 6.4% to $5.73 premarket while Banco Santander SA (STD) dropped 5.8% to $5.33. Interline Brands Inc. (IBI) has agreed to go private in a cash deal that values the distributor of maintenance and repair products at roughly $811 million. The company's agreement with GS Capital Partners and P2 Capital Partners offers shareholders $25.50 a share in cash, a 42% premium to the stock's Friday closing price. Shares jumped 41% to $25.34 premarket. Patriot Coal Corp. (PCX) has named a new chief executive, Irl F. Engelhardt, to replace Richard M. Whiting as the company struggles to maintain its financial footing in a challenging market for coal. Separately, Goldman Sachs upgraded its stock-investment rating on Peabody to buy from neutral, saying it finds U.S. coal stocks "attractive" following a recent selloff. In addition to Peabody, the firm called SunCoke Energy (SXC) and Consol Energy (CNG) its favorites. Shares of Peabody rose 4.7% to $14.44 premarket, while Consol Energy climbed 2.6% to $30.36 in light premarket trading. Watchlist: Trustmark Corp. (TRMK) agreed to acquire BancTrust Financial Group Inc. (BTFG) in a deal valued at about $55.4 million that gives Trustmark a presence in the Alabama market. BancTrust holders will receive 0.125 shares of Trustmark common stock for each BancTrust share. Based on Trustmark's closing price of $24.66 Friday, the deal values BancTrust at about $3.08 a share, a 62% premium to its Friday close of $1.90. Total pay for Rite Aid Corp.'s (RAD) top executives jumped sharply higher in fiscal 2012 due to long-term cash incentive units that vested after the company reached adjusted earnings targets for the past three years. In a separate press release, Rite Aid disclosed Friday that the company's board elected President and Chief Executive John Standley to the additional position of chairman, effective next month. Sanderson Farms Inc. (SAFM) swung to a fiscal second-quarter profit as increased prices and production returned the poultry company to profitability. Watson Pharmaceuticals Inc. (WPI) reached a settlement with Endo Pharmaceuticals Inc. that resolves patent infringement lawsuits related to its generic version of the Lidoderm patch. The Endo Health Solutions Inc. (ENDP) unit had been seeking to block Watson from selling a generic version of Lidoderm before a U.S. patent for Lidoderm expires in 2015. -Edited By Corrie Driebusch and Nathalie Tadena, Dow Jones Newswires; 212-416-2143;

Stock News for Chesapeake (CHK)
11/24/201516:56:00MARKET SNAPSHOT: Stocks Close Slightly Higher As Jump In Oil...
11/24/201514:58:00MARKET SNAPSHOT: Stocks Shake Off Geopolitical Jitters, Erase...
11/24/201511:00:035 Things Apache Corporation's CEO Wants You to Know
11/21/201511:00:13This Dividend Only Has One Way to Go
11/20/201516:58:43Why Chesapeake Energy, Sunoco, and PBF Energy Made Big Moves...
11/19/201519:40:03Why Chesapeake Energy, Tenet Healthcare, and JinkoSolar Slumped...
11/17/201516:00:03Making Sense of SandRidge Energy Inc.’s Most Recent Acquisition
11/16/201516:05:00Chesapeake Energy Corporation Announces The Expiration And Final...
11/16/201513:05:543 Stocks We're Watching in the Fourth Quarter
11/14/201510:15:03Is Freeport McMoRan Inc. Under Attack, or Have Investors Found...
11/14/201507:45:02Denbury Resources' Headline Earnings Hide Some Promising Signs...
11/10/201512:30:13The 3 Most Important Numbers from Halcon Resources Corp's Earnings
11/04/201512:00:103 Key Numbers From Chesapeake Energy Corporation's Earnings
11/04/201509:42:00Chesapeake Energy Swings to Loss on Impairments -- Update
11/04/201508:50:00Chesapeake Swings to Loss on Impairments
11/04/201508:44:00Chesapeake Swings to Loss on Impairments
11/04/201507:00:00Chesapeake Energy Corporation Reports 2015 Third Quarter Financial...
10/30/201503:42:58No Bottom For Commodities Or Valeant - Bezek's Daily Briefing
10/27/201501:04:15Is It Finally Time To Buy Natural Gas?
10/24/201512:20:05Freeport-McMoRan's Results Keep Looking Scarier

Chesapeake Energy and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations